Tema Oncology ETF (NASDAQ:CANC – Get Free Report) was the target of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 8,604 shares, a decrease of 67.6% from the April 15th total of 26,566 shares. Based on an average daily volume of 36,832 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.2% of the shares of the stock are sold short.
Tema Oncology ETF Price Performance
CANC traded down $1.09 on Friday, hitting $36.88. 10,932 shares of the stock were exchanged, compared to its average volume of 32,259. Tema Oncology ETF has a 12 month low of $22.78 and a 12 month high of $39.95. The business has a 50-day moving average of $37.23 and a two-hundred day moving average of $35.84. The firm has a market capitalization of $172.97 million, a price-to-earnings ratio of 20.39 and a beta of 0.74.
Institutional Investors Weigh In On Tema Oncology ETF
Several institutional investors and hedge funds have recently bought and sold shares of CANC. Thrivent Financial for Lutherans lifted its position in Tema Oncology ETF by 891.1% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,461,649 shares of the company’s stock worth $50,747,000 after purchasing an additional 1,314,177 shares during the period. Jane Street Group LLC acquired a new position in Tema Oncology ETF during the fourth quarter worth about $1,100,000. Flow Traders U.S. LLC acquired a new position in shares of Tema Oncology ETF in the third quarter valued at approximately $630,000. LPL Financial LLC acquired a new position in shares of Tema Oncology ETF in the fourth quarter valued at approximately $278,000. Finally, Roxbury Financial LLC acquired a new position in shares of Tema Oncology ETF in the first quarter valued at approximately $34,000.
Tema Oncology ETF Company Profile
The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.
Featured Stories
- Five stocks we like better than Tema Oncology ETF
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Tema Oncology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tema Oncology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
